Kayfanda
Ipsen’s cabozantinib accepted by SMC for adults with advanced neuroendocrine tumours
NETs affect approximately seven per 100,000 people in Scotland
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
CSL’s Privigen approved as measles treatment by European Commission
Cases of measles have been rising in Europe since 2023
Ipsen appoints Michelle Werner as Executive Vice President, President of North America
Werner previously held senior roles at Bristol Myers Squibb, AstraZeneca and Novartis
PureTech’s deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis
Rare diseases are defined as conditions affecting fewer than 200,000 people in the US or fewer than five in 10,000 individuals in the European Union
Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations
Lefranc has served at Ipsen since 2013, most recently as Senior Vice President
Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn
The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials
Lilly’s early Alzheimer’s disease treatment approved in the EU
Marketing authorisation follows positive late-stage trial results
Ipsen’s tumour treatment receives MHRA marketing authorisation
This is the first approval in the UK for previously treated advanced neuroendocrine tumours
Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours
Treatment options following disease progression have previously been limited for many patients
Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma
The drug is already approved in the EU across three other multiple myeloma indications